2024-02-08 08:40:00 ET
Summary
- In a vacuum, SHC screens as my ideal type of business.
- SHC is diversified across almost all major medical device and pharmaceutical manufacturers, boasts a 100% retention rate.
- I estimate SHC will earn $700MM in 2026 EBITDA and $1.50 in 2026 EPS.
The following segment was excerpted from this fund letter.
Sotera Health Company ( SHC )
In a vacuum, SHC screens as my ideal type of business: one half of a duopoly market with good long-term growth where the product sold is mission critical to customers, with high switching costs, yet the product's cost is immaterial to their customers....
Read the full article on Seeking Alpha
For further details see:
McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount